Theriva Biologics (TOVX) Total Non-Current Liabilities (2013 - 2026)
Theriva Biologics (TOVX) posted quarterly Total Non-Current Liabilities of $14.0 million for Q1 2026, up 27.62% year-over-year from $11.0 million in Q1 2025, and up 9.02% quarter-over-quarter from $12.9 million in Q4 2025.
Theriva Biologics (TOVX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Total Non-Current Liabilities for 12 consecutive years, with $14.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 27.62% year-over-year to $14.0 million; the TTM figure through Mar 2026 stood at $14.0 million (up 27.62% YoY), while the FY2025 annual figure was $12.9 million, up 38.02% from the prior year.
- Total Non-Current Liabilities rose to $14.0 million in Q1 2026 per TOVX's latest filing, from $12.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $16.2 million in Q2 2022 and bottomed at $8.1 million in Q1 2024.
- Historically, Total Non-Current Liabilities has averaged $11.6 million across 5 years, with a median of $11.7 million in 2023.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities plunged 31.63% — and 2025, when it jumped 76.13%.
- Theriva Biologics' Total Non-Current Liabilities stood at $10.1 million in 2022, then declined by 8.31% to $9.2 million in 2023, then increased by 0.69% to $9.3 million in 2024, then soared by 38.02% to $12.9 million in 2025, then climbed by 9.02% to $14.0 million in 2026.
- Business Quant data shows TOVX's Total Non-Current Liabilities at $14.0 million in Q1 2026, $12.9 million in Q4 2025, and $13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | 15.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.50 Mn |
| Mar 31, 2026 | 14.01 Mn |
| Dec 31, 2025 | 12.85 Mn |
| Sep 30, 2025 | 13.31 Mn |
| Jun 30, 2025 | 15.05 Mn |
| Mar 31, 2025 | 10.98 Mn |
| Dec 31, 2024 | 9.31 Mn |
| Sep 30, 2024 | 8.69 Mn |
| Jun 30, 2024 | 8.54 Mn |
| Mar 31, 2024 | 8.13 Mn |
| Dec 31, 2023 | 9.25 Mn |
| Sep 30, 2023 | 11.73 Mn |
| Jun 30, 2023 | 11.92 Mn |
| Mar 31, 2023 | 11.89 Mn |
| Dec 31, 2022 | 10.09 Mn |
| Sep 30, 2022 | 15.75 Mn |
| Jun 30, 2022 | 16.23 Mn |
| Mar 31, 2022 | 9.87 Mn |
| Sep 30, 2019 | 6.17 Mn |
| Jun 30, 2019 | 4.41 Mn |